首页> 外文期刊>BMC Cardiovascular Disorders >Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus
【24h】

Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus

机译:巴沙地平与乐卡地平除氯沙坦相比对氯吡坦对高血压和2型糖尿病患者的内皮损伤和氧化应激参数的影响

获取原文
           

摘要

Background Essential hypertension has been extensively reported to cause endothelial dysfunction. The aim of this study was to evaluate the effects of barnidipine or lercanidipine, in addition to losartan, on some parameters indicative of endothelial damage and oxidative stress in hypertensive, type 2 diabetic patients. Methods One hundred and fifty one patients were randomised to barnidipine, 20?mg/day, or lercanidipine, 20?mg/day, both in addition to losartan, 100?mg/day, for 6?months. We assessed BP every month, in addition, patients underwent ambulatory blood pressure monitoring (ABPM). We also assessed: fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), some markers such as high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), metalloproteinase-2 (MMP-2) and -9 (MMP-9), soluble vascular adhesion protein-1 (sVCAM-1), soluble intercellular adhesion protein-1 (sICAM-1), isoprostanes and paraoxonase-1 (PON-1). Results Both barnidipine and lercanidipine resulted in a significant reduction in blood pressure, even if the reduction obtained with barnidipine?+?losartan was greater than that obtained with lercanidipine?+?losartan. Data recorded with ABPM also showed a similar trend. Barnidipine?+?losartan reduced the levels of Hs-CRP, TNF-α, sVCAM-1, sICAM-1, and isoprostanes both compared to baseline and to lercanidipine?+?losartan. Conclusions Barnidipine?+?losartan gave an improvement of some parameters indicative of endothelial damage and oxidative stress in diabetic and hypertensive patients. Trial registration NCT02064218 , ClinicalTrials.gov
机译:背景技术已经广泛报道了原发性高血压会引起内皮功能障碍。这项研究的目的是评估除氯沙坦外,巴尼地平或莱卡地平对某些指示2型糖尿病高血压患者内皮损伤和氧化应激的参数的影响。方法115名患者被随机分为6个月,除氯沙坦100毫克/天外,随机选择巴尼地平20毫克/天或乐卡地平20毫克/天,两者均服用。我们每月都对BP进行评估,此外,对患者进行动态血压监测(ABPM)。我们还评估了:空腹血糖(FPG),糖化血红蛋白(HbA 1c ),一些标志物,例如高敏C反应蛋白(Hs-CRP),肿瘤坏死因子-α(TNF- α),金属蛋白酶2(MMP-2)和-9(MMP-9),可溶性血管粘附蛋白1(sVCAM-1),可溶性细胞间粘附蛋白1(sICAM-1),异前列腺素和对氧磷酶1( PON-1)。结果巴尼地平和乐卡地平均导致血压显着降低,即使使用巴尼地平+氯沙坦的降压幅度大于使用乐卡地平+ +氯沙坦的降压幅度也是如此。用ABPM记录的数据也显示出类似的趋势。与基线和乐卡地平+ +氯沙坦相比,巴尼地平+ +氯沙坦均降低了Hs-CRP,TNF-α,sVCAM-1,sICAM-1和异前列腺素的水平。结论Barnidipine?+?losartan改善了一些指示糖尿病和高血压患者内皮损伤和氧化应激的参数。试用注册NCT02064218,ClinicalTrials.gov

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号